GPI-1485 (Guilford).
GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.
Marshall
Victoria L
VL
Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK.
Grosset
Donald G
DG
D000284:Administration, Oral; D000818:Animals; D000978:Antiparkinson Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy; D010330:Patents as Topic; D011468:Prostatectomy / Q000009:adverse effects; D013329:Structure-Activity Relationship; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000978:Antiparkinson Agents; C486238:GPI 1485; D016559:Tacrolimus